Valuation: BioNTech SE

Capitalization 27.28B 28.61B 25.42B 22.53B 40.59B 2,428B 44.82B 314B 117B 998B 108B 105B 4,355B P/E ratio 2024 *
-37.7x
P/E ratio 2025 * -34.4x
Enterprise value 14.32B 15.02B 13.35B 11.83B 21.31B 1,275B 23.54B 165B 61.18B 524B 56.45B 55.18B 2,287B EV / Sales 2024 *
5.44x
EV / Sales 2025 * 5.8x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: BioNTech SE

1 day+1.13%
1 week+5.22%
Current month+1.94%
1 month+11.00%
3 months+21.58%
6 months+22.16%
Current year+14.35%
More quotes
1 week
116.73
Extreme 116.73
125.40
1 month
94.31
Extreme 94.31
125.40
Current year
76.53
Extreme 76.5301
131.49
1 year
76.53
Extreme 76.5301
131.49
3 years
76.53
Extreme 76.5301
302.34
5 years
27.73
Extreme 27.7279
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Director TitleAgeSince
Chief Tech/Sci/R&D Officer 57 2017-12-31
Chief Executive Officer 59 2008-06-01
Director of Finance/CFO 60 2021-06-30
Manager TitleAgeSince
Chairman 54 2008-06-01
Director/Board Member 67 2008-06-01
Director/Board Member 63 2017-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+1.13%+5.22%+20.10%-53.16%28.61B
-0.89%+0.03%+30.26%+123.07%121B
-4.14%-1.76%-12.66%+10.67%83.17B
+0.24%-1.39%+39.17%+121.73%36.73B
-1.04%+10.90%-25.58%-59.19%22.76B
-2.23%-9.45%+3.28%-39.59%19.59B
-3.12%-2.65%-32.67%-40.93%14.3B
-4.79%+1.53%+750.95%+260.28%13.84B
-2.90%-4.39%+164.31%+173.02%13.27B
-1.12%-0.74%+6.99%+59.18%12.98B
Average -1.36%+0.92%+94.42%+55.51% 36.58B
Weighted average by Cap. -1.55%+1.38%+44.53%+61.88%
See all sector performances

Financials

2024 *2025 *
Net sales 2.63B 2.76B 2.45B 2.17B 3.92B 234B 4.33B 30.34B 11.25B 96.36B 10.38B 10.15B 420B 2.59B 2.71B 2.41B 2.14B 3.85B 230B 4.25B 29.82B 11.06B 94.71B 10.2B 9.97B 413B
Net income -782M -820M -729M -646M -1.16B -69.62B -1.29B -9.01B -3.34B -28.62B -3.08B -3.01B -125B -797M -836M -743M -658M -1.19B -70.97B -1.31B -9.19B -3.41B -29.17B -3.14B -3.07B -127B
Net Debt -12.95B -13.59B -12.07B -10.7B -19.28B -1,153B -21.29B -149B -55.33B -474B -51.06B -49.91B -2,068B -12.27B -12.87B -11.44B -10.14B -18.26B -1,093B -20.17B -141B -52.43B -449B -48.38B -47.29B -1,960B
More financial data * Estimated data
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
6,133
Calendar
More about the company
Date Price Change Volume
24-12-12 120.69 $ +1.13% 660,594
24-12-11 119.34 $ +2.13% 679,018
24-12-10 116.85 $ -3.29% 554,593
24-12-09 120.82 $ -0.74% 538,537
24-12-06 121.72 $ +2.42% 992,446

Delayed Quote Nasdaq, December 12, 2024 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart BIONTECH-SEMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
115.07EUR
Average target price
131.04EUR
Spread / Average Target
+13.89%
Consensus

Quarterly revenue - Rate of surprise